Galleri Blood Test Fails to Reduce Late-Stage Cancer Diagnoses in Major Trial

A major clinical trial has found that the Galleri multi-cancer early detection test failed to achieve its primary objective of reducing late-stage cancer diagnoses.

The data was presented on May 30, 2026, at an oncology conference in Chicago, which is described as the world’s largest cancer conference. According to reporting by The Guardian, the results indicate that the test did not meet its main goal.

The study involved 142,000 patients from the National Health Service (NHS) in the United Kingdom. The trial was designed to assess whether adding the Galleri test to standard screening protocols could shift cancer diagnoses to earlier and more treatable stages.

The blood test, which screens for more than 50 types of cancer, had previously been billed as the holy grail of oncology.

Despite the expectations surrounding the technology, the findings presented in Chicago show that the test failed to achieve the intended shift toward earlier detection in the studied NHS population.